解毒消瘤方提高B细胞非霍奇金淋巴瘤患者无进展生存期的回顾性队列研究

胡明; 狄前程; 胡琦; 冯晓卫; 魏聪敏; 李军民; 赵维莅

doi:10.3969/j.issn.2095-6606.2023.01.008

您当前的位置：

首页 >

文章列表页 >

解毒消瘤方提高B细胞非霍奇金淋巴瘤患者无进展生存期的回顾性队列研究

临床研究 | 更新时间：2023-02-02

- 解毒消瘤方提高B细胞非霍奇金淋巴瘤患者无进展生存期的回顾性队列研究
- A retrospective cohort study of Jiedu Xiaoliu Formula improving progression-free survival in patients with B-cell non-Hodgkin’s lymphoma
- 现代中医临床 2023年30卷第1期页码：31-37
- 作者机构：
  
  1.上海中医药大学附属市中医医院　上海　200071
  2.河南郑州颐和医院中医科
  3.上海交通大学附属瑞金医院
- 作者简介：
  
  胡明，男，在读硕士生
  #胡琦，女，博士，副主任医师，硕士生导师，E-mail：queenhu_cn@aliyun.com
- 基金信息：
  
  上海市中医药管理局资助项目(B01B1);上海市科学技术委员会资助项目(18401903900)
- DOI：10.3969/j.issn.2095-6606.2023.01.008
  中图分类号： R273
- 纸质出版日期：2023-01-30，
  
  收稿日期：2022-04-09，
- 稿件说明：
移动端阅览
胡明, 狄前程, 胡琦, 等. 解毒消瘤方提高B细胞非霍奇金淋巴瘤患者无进展生存期的回顾性队列研究[J]. 现代中医临床, 2023,30(1):31-37.

HU Ming, DI Qiancheng, HU Qi, et al. A retrospective cohort study of Jiedu Xiaoliu Formula improving progression-free survival in patients with B-cell non-Hodgkin’s lymphoma[J]. Modern Chinese Clinical Medicine, 2023,30(1):31-37.
胡明, 狄前程, 胡琦, 等. 解毒消瘤方提高B细胞非霍奇金淋巴瘤患者无进展生存期的回顾性队列研究[J]. 现代中医临床, 2023,30(1):31-37. DOI： 10.3969/j.issn.2095-6606.2023.01.008.

HU Ming, DI Qiancheng, HU Qi, et al. A retrospective cohort study of Jiedu Xiaoliu Formula improving progression-free survival in patients with B-cell non-Hodgkin’s lymphoma[J]. Modern Chinese Clinical Medicine, 2023,30(1):31-37. DOI： 10.3969/j.issn.2095-6606.2023.01.008.

摘要

目的

观察解毒消瘤方对B细胞非霍奇金淋巴瘤(B-NHL)患者无进展生存期(PFS)的影响。

方法

将357例B-NHL患者根据接受解毒消瘤方治疗时间是否大于3个月，分为对照组214例，中医组143例，倾向性评分匹配(PSM)后对照组118例，中医组118例。观察PFS和中位无进展生存期(mPFS)、Kaplan-Meier累计PFS率、危险比(

)。

结果

PSM后，中医组与对照组的mPFS分别为76(45.48，106.52)个月和50(28.16，71.85)个月(

＝6.82，

＝0.009)。2年Kaplan-Meier累计PFS率中医组高于对照组，差异有统计学意义(

0.05)。2组低危Ⅰ～Ⅱ期B-NHL患者，中医组mPFS为76(14.72，137.28)个月，对照组mPFS为78(38.05，117.95)个月，中医组低于对照组，差异有统计学意义(

0.05)。有侵袭性B-NHL患者中，中医组mPFS未达到，对照组mPFS为36(26.73，45.26)个月，2组间比较差异有统计学意义(

0.05)。采用Cox回归分析不同亚组HR，结果显示：中医组与对照组相比HR＝0.91(

0.05)。其中，男性、不低于60岁、侵袭性、Ⅲ～Ⅳ期、B症状、血清乳酸脱氢酶(LDH)升高、基础疾病，ECOGE评分1～2分、放化疗、弥漫大B细胞淋巴瘤(DLBCL)对B-NHL患者进展风险的影响具有统计学意义(

0.05)。

结论

解毒消瘤方可延缓体力状态良好、低危Ⅰ～Ⅱ期、有侵袭性B-NHL患者PFS。

Abstract

Objective

To observe the effect of Jiedu Xiaoliu Formula (Toxin-Resolving and Tumor-Removing Formula) on progression-free survival (PFS) in patients with B cell non-Hodgkin’s lymphoma (B-NHL).

Methods

357 patients with B-NHL were divided into the control group (214 cases) and TCM group (143 cases). After propensity score matching (PSM)

118 cases remained in both groups. The PFS

median progression free survival (mPFS)

Kaplan Meier cumulative PFS rate and hazard ratio (

) were observed.

Results

After PSM

the mPFS of the TCM group and control group were 76 (45.48

106.52) months and 50 (28.16

71.85) months

respectively (

=6.82

=0.009). The Kaplan Meier cumulative PFS rate in the TCM group was higher than that in the control group in two years

with a statistically significant difference (

0.05). The mPFS of the two groups of low-risk patients with B-NHL in stages I to II was 76 (14.72

137.28) months in the TCM group and 78 (38.05

117.95) months in the control group. The difference was statistically significant (

0.05). In patients with invasive B-NHL

the mPFS in the TCM group was not reached

while that in the control group was 36 (26.73

45.26) months. The difference between the two groups was statistically significant (

0.05). Cox regression analysis was used to analyze HR of different subgroups. The result showed that HR of the TCM group was 0.91 (

0.05) compared with that of the control group. Factors including male

no less than 60 years old

invasive

stage III-IV

B symptoms

elevated LDH

underlying health conditions

ECOGE score of 1-2

radiotherapy and chemotherapy

and DLBCL had statistically significant effects on the risk of progression of B-NHL patients (P

0.05).

Conclusion

Jiedu Xiaoliu Formula can delay PFS in patients with good physical condition

low-risk stage I-II

and invasive B-NHL.

关键词

B细胞非霍奇金淋巴瘤解毒消瘤方邪去则正安无进展生存期

Keywords

B-cell non-Hodgkin’s lymphomaJiedu Xiaoliu Formulahealthy qi settle down when evil is removedprogression-free survival

references

CAO W，CHEN H D，YU Y W，et al.Changing profiles of cancer burden worldwide and in China：a secondary analysis of the global cancer statistics 2020[J].Chin Med J(Engl)，2021，134(7): 209-249.

SUNG H，FERLAY J，SIEGEL R L，et al.Global cancer statistics 2020：GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J].CA Cancer J Clin，2021，71(3): 783-791.

SUNJ Y L.Distribution of lymphoid neoplasms in China：analysis of 4，638 cases according to the World Health Organization classification[J].Am J Clin Pathol，2012，138(3): 429-434.

花京剩，罗爽，仇惠英.吉西他滨对比长春瑞滨化疗方案治疗复发性非霍奇金淋巴瘤的临床疗效和不良反应观察[J].临床血液学杂志，2020，33(7): 493-497.

ROSCHEWSKI M，STAUDT L M，WILSON W H.Diffuse large B-cell lymphoma-treatment approaches in the molecular era[J].Nat Rev Clin Oncol，2014，11(1): 12-23.

LU J P，WANG F X，WEN S P，et al.Haploidentical hematopoietic stem cell transplantation with ‘Beijing protocol’ in the treatment of T-lymphoblastic lymphoma[J].Leuk Lymphoma，2020，61(11): 2748-2751.

LI L,LI Y,QUE X,et al.Prognostic significances of overexpression MYC and/or BCL2 in R-CHOP-treated diffuse large B-cell lymphoma:a systematic review and meta-analysis[J/OL].Sci Rep,2018,8(1):6267[2022-04-09].https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5908914/.

CAMICIA R,WINKLER H C,HASSA P O.Novel drug targets for personalized precision medicine in relapsed/refractory diffuse large B-cell lymphoma: a comprehensive review[J/OL].Mol Cancer,2015,14:207[2022-04-09].https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4676894/.

SABATTINI E，BACCI F，SAGRAMOSO C，et al.WHO classification of tumours of haematopoietic and lymphoid tissues in 2008：an overview[J].Pathologica，2010，102(3): 83-87.

CHESON B D.Staging and response assessment in lymphomas:the new Lugano classification[J/OL].Chin Clin Oncol,2015,4(1):5[2022-04-09].https://www.ncbi.nlm.nih.gov/pmid/articles/ PMID: 25841712/.

OKEN M M，CREECH R H，TORMEY D C，et al.Toxicity and response criteria of the Eastern Cooperative Oncology Group[J].Am J Clin Oncol，1982，5(6): 649-655.

YOUNES A，HILDEN P，COIFFIER B，et al.International working group consensus response evaluation criteria in lymphoma (RECIL 2017)[J].Ann Oncol，2017，7(28): 1436-1447.

王双双，胡兵，安红梅.恶性淋巴瘤中医病机与治疗[J].世界科学技术－中医药现代化，2014，16(11): 2425-2429.

中国中西医结合学会血液学专业委员会淋巴瘤专家委员会.淋巴瘤中西医结合诊疗专家共识(2020年)[J].中国中西医结合杂志，2021，41(9): 1036-1041.

葛洪.肘后备急方[M].汪剑，邹运国，罗思航，整理.中国中医药出版社，2016: 284.

黄珊，江劲波.江劲波教授治疗淋巴瘤经验[J].中国中医药现代远程教育，2020，18(23): 61-63.

顾恪波，何立丽，张丽娜，等.孙桂芝辨治恶性淋巴瘤经验[J].中华中医药杂志，2020，35(12): 6125-6128.

LIU J H，CHEN C C，BAI L Y，et al.Predictors for successful mobilization of peripheral blood progenitor cells with ESHAP＋G-CSF in patients with pretreated non-Hodgkin’s lymphoma[J].J Chin Med Assoc，2008，71(6): 279-285.

ITOH K，OHTSU T，FUKUDA H，et al.Randomized phase II study of biweekly CHOP and dose-escalated CHOP with prophylactic use of lenograstim (glycosylated G-CSF) in aggressive non-Hodgkin’s lymphoma：Japan clinical oncology group study 9505[J].Ann Oncol，2002，13(9): 1347-1355.

张从正.儒门事亲[M].邓铁，赖畴，吴伟，整理.北京：人民卫生出版社，2019: 139-140.

程卓，赵文豪，黄旭，等.石见穿多糖对H22荷瘤小鼠的抗肿瘤免疫调节作用[J].天然产物研究与开发，2016，28(6): 846-851.

朱伟嵘，沈小珩，王洁.中药天然成分抗非霍奇金淋巴瘤的协同机制实验研究进展[J].中成药，2015，37(7): 1544-1547.

张涛，苍薇，田黎明，等.紫花地丁对U14荷瘤鼠抑瘤作用的实验研究[J].时珍国医国药，2011，22(12): 2926-2927.

郑佳彬，王学谦，刘杰.林洪生教授治疗恶性淋巴瘤经验发微[J].环球中医药，2016，9(2): 206-208.

傅华，贾新颜，程毅敏，等.甘欣锦运用扶正化痰散结法治疗老年恶性淋巴瘤经验撷英[J].西部中医药，2015，28(4): 54-55.

田建辉，罗斌，阙祖俊，等.癌症转移亚临床阶段核心病机“正虚伏毒”学说[J].上海中医药杂志，2021，55(10): 1-3.

孙媛媛，张明智.乙型肝炎病毒感染的弥漫大B细胞淋巴瘤患者临床特点及预后分析[J].医学研究生学报，2019，32(3): 253-257.

王雅婧，张红玲，宋鹤，等.结外NK/T细胞淋巴瘤预后因素的研究进展[J].中华病理学杂志，2021，50(6): 691-694.

张玉林，田亚坤，郭彩萍，等.获得性免疫缺陷综合征相关淋巴瘤的诊治进展[J].白血病·淋巴瘤，2018，27(6): 376-379.

孙晓红，万顺，李子坚.抗病毒治疗在HCV相关淋巴瘤中的治疗现状及研究进展[J].中国实验血液学杂志，2021，29(6): 1987-1990.

浏览量

115

下载量

CSCD

文章被引用时，请邮件提醒。

提交

工具集

关联资源

暂无数据